Stock Analiz

Cue Biopharma, Inc. CUE

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$16.12Market cap $117M
Open the interactive analysis →

Cue Biopharma, Inc. (CUE) is a healthcare company listed in the US with a market value of about $117M. In the twelve months to June 30, 2026 it had revenue of $38M and net income of -$164M, a net margin of -435.8%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 54% a year, a 5-year average ROIC of -83%.

About Cue Biopharma

Cue Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $1M in 2018 to $27M in 2025, growth of about 57.5% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 166% over three years (dilution for shareholders). It spends 137% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.1
P/B50.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-42.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)195.8%
Revenue growth (5 yrs, per year)54.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1202.5%
ROIC (5-yr avg.)-83.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$38M$27M$9M$5M$1M$15M$3M$3M$1M—
Net income-$164M-$27M-$41M-$51M-$53M-$44M-$45M-$37M-$39M-$23M
Free cash flow-$50M-$22M-$36M-$40M-$42M-$40M-$33M-$31M-$28M-$13M
EPS (diluted)$-25.26$-0.28$-0.72$-1.11$-1.49$-1.41$-1.56$-1.66$-1.94$-2.16
Net margin-435.8%-96.9%-438.0%-924.1%-4257.8%-295.6%-1419.8%-1061.2%-3411.5%—
ROIC—-68.5%-148.5%-91.0%-62.6%-45.7%-41.3%-48.1%-90.0%-29.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Cue Biopharma pay a dividend?

Not currently.

Is Cue Biopharma a good stock to buy?

We do not give buy or sell advice. Cue Biopharma scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.